Dong Yuancai, Ng Wai Kiong, Shen Shoucang, Kim Sanggu, Tan Reginald B H
Institute of Chemical and Engineering Sciences, 1 Pesek Road, Jurong Island, Singapore 627833, Singapore.
Int J Pharm. 2009 Jun 22;375(1-2):84-8. doi: 10.1016/j.ijpharm.2009.03.013. Epub 2009 Mar 24.
Due to low aqueous solubility and slow dissolution rate, spironolactone, a synthetic steroid diuretic, has a low and variable oral bioavailability. Nanoparticles were thus prepared by antisolvent precipitation in this work for accelerating dissolution of this kind of poorly water-soluble drugs. Effects of surfactant type/concentration and feed drug concentration on the precipitated particle size were evaluated. It was found that introduction of spironolactone solution in N-methyl-2-pyrrolidone (NMP) to the antisolvent water can produce the particles in the submicron range with hydroxypropyl methylcellulose (HPMC) as the stabilizer. The particle size decreased with the increase of HPMC concentration from 0 to 0.125% (w/v), further increase of which did not affect the size significantly. Increasing feed drug concentration from 10 to 100 mg/ml resulted in the particle size decrease. In comparison with raw drug, the chemical structure of nanosized spironolactone was not changed but the crystallinity was reduced. Dissolution of spironolactone nanoparticles in 0.1M HCl was 2.59 times faster than raw drugs in 60 min.
由于螺内酯(一种合成甾体利尿剂)的水溶性低且溶解速率慢,其口服生物利用度低且不稳定。因此,本研究通过反溶剂沉淀法制备纳米颗粒,以加速这类难溶性药物的溶解。评估了表面活性剂类型/浓度和药物进料浓度对沉淀粒径的影响。研究发现,以羟丙基甲基纤维素(HPMC)为稳定剂,将螺内酯在N-甲基-2-吡咯烷酮(NMP)中的溶液引入反溶剂水,可以制备出亚微米级的颗粒。粒径随着HPMC浓度从0增加到0.125%(w/v)而减小,进一步增加HPMC浓度对粒径影响不大。将药物进料浓度从10 mg/ml增加到100 mg/ml会导致粒径减小。与原料药相比,纳米级螺内酯的化学结构未发生变化,但结晶度降低。螺内酯纳米颗粒在0.1M HCl中的溶解速度在60分钟内比原料药快2.59倍。